Alector, Inc. (NASDAQ:ALEC) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lessened its stake in Alector, Inc. (NASDAQ:ALEC) by 10.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 56,286 shares of the company’s stock after selling 6,900 shares during the quarter. Los Angeles Capital Management LLC owned about 0.06% of Alector worth $262,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ALEC. Allspring Global Investments Holdings LLC purchased a new position in shares of Alector in the first quarter valued at $40,000. Swiss National Bank increased its holdings in Alector by 6.5% during the 1st quarter. Swiss National Bank now owns 131,900 shares of the company’s stock worth $794,000 after purchasing an additional 8,000 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Alector by 9.9% in the 1st quarter. Russell Investments Group Ltd. now owns 78,348 shares of the company’s stock valued at $472,000 after purchasing an additional 7,066 shares in the last quarter. ProShare Advisors LLC boosted its stake in shares of Alector by 24.1% during the 1st quarter. ProShare Advisors LLC now owns 19,709 shares of the company’s stock valued at $119,000 after buying an additional 3,827 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Alector by 12.0% during the first quarter. Vanguard Group Inc. now owns 4,912,578 shares of the company’s stock worth $29,574,000 after buying an additional 526,037 shares in the last quarter. Institutional investors and hedge funds own 85.83% of the company’s stock.

Insider Activity at Alector

In related news, CFO Marc Grasso sold 7,297 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $35,609.36. Following the completion of the sale, the chief financial officer now owns 130,740 shares of the company’s stock, valued at $638,011.20. This represents a 5.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Arnon Rosenthal sold 26,499 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total transaction of $129,315.12. Following the completion of the sale, the chief executive officer now directly owns 1,948,746 shares of the company’s stock, valued at approximately $9,509,880.48. This represents a 1.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,722 shares of company stock worth $232,883 in the last ninety days. 9.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ALEC has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alector in a report on Tuesday, September 17th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Alector in a research report on Thursday, November 7th.

Alector Stock Performance

Shares of NASDAQ:ALEC opened at $3.76 on Tuesday. The company’s fifty day moving average is $5.10 and its two-hundred day moving average is $5.12. Alector, Inc. has a 1-year low of $3.69 and a 1-year high of $8.90. The stock has a market capitalization of $368.22 million, a price-to-earnings ratio of -2.19 and a beta of 0.66.

Alector (NASDAQ:ALEC) last issued its earnings results on Wednesday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.10. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. The firm had revenue of $15.34 million for the quarter, compared to analysts’ expectations of $16.33 million. Sell-side analysts expect that Alector, Inc. will post -1.87 EPS for the current fiscal year.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.